Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3071 Hormonal Ectopic Secretion Syndromes Associated to Neuroendocine Neoplasia

Introduction: Neuroendocrine neoplasias (NEN) are able to produce and secrete bioactive peptides and cause distinct syndromes related to their biological effects. The outcome will depend on the oncological disease as well as the hormonal syndrome

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belli S

Authors: Belli S, Tkatch J, O'Connor J, Martinez M, Paissan A,

Keywords: ectopic secretion, hormonal syndrome, neuroendocrine neoplasia,

#3046 Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al). We report more recent data with more accurate coding (ICD-O-3).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: White B, Bouvier C, Genus T, Rous B, Srirajaskanthan R,

Keywords: Epidemiology, Neuroendocrine Neoplasia, Incidence, Prevalence, population data, histopathology,

#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis

Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,

Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia

Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Unger N, Theurer S, Herold T, Weber F, Dralle H,

Keywords: Somatic Mutations, NGS, Somatostatin receptor subtypes, Intestinal NEN,